Top Page
Orthocell Ltd
(Sydney:OCC)
Orthocell Ltd (OCC) vs. iShares MSCI Australia ETF (EWA)
Orthocell Ltd Business Overview & Revenue Model
Orthocell Ltd Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.41M | 7.55M | 5.32M | 4.24M | 1.53M | 1.02M |
| Gross Profit | 3.50M | 4.80M | 3.69M | 3.06M | 832.52K | 299.88K |
| EBITDA | -15.31M | -13.43M | -11.68M | -10.34M | -11.52M | -11.67M |
| Net Income | -12.48M | -8.57M | -7.18M | -6.25M | -9.11M | -9.04M |
Balance Sheet | ||||||
| Total Assets | 59.80M | 35.24M | 26.62M | 29.61M | 37.90M | 19.33M |
| Cash, Cash Equivalents and Short-Term Investments | 44.37M | 28.62M | 20.61M | 24.82M | 11.02M | 16.33M |
| Total Debt | 835.79K | 576.89K | 689.69K | 562.30K | 507.56K | 621.72K |
| Total Liabilities | 18.64M | 20.67M | 22.08M | 23.46M | 27.99M | 2.46M |
| Stockholders Equity | 41.16M | 14.57M | 4.53M | 6.15M | 9.90M | 16.87M |
Cash Flow | ||||||
| Free Cash Flow | -12.21M | -9.04M | -7.45M | 13.96M | -6.80M | -4.82M |
| Operating Cash Flow | -12.05M | -8.68M | -6.51M | 14.59M | -6.26M | -4.63M |
| Investing Cash Flow | -42.26M | -359.06K | -942.02K | -631.56K | -535.02K | -188.52K |
| Financing Cash Flow | 30.84M | 17.05M | 3.24M | -164.61K | 1.49M | 709.15K |
Orthocell Ltd Technical Analysis
Orthocell Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$113.45M | -1.51 | -265.55% | ― | -20.79% | 73.98% | |
44 Neutral | AU$192.13M | -5.17 | -83.97% | ― | 1271.12% | 36.87% | |
42 Neutral | AU$80.88M | -14.80 | -40.65% | ― | 700.00% | 26.88% | |
41 Neutral | AU$195.34M | -12.98 | -44.80% | ― | 42.05% | -0.84% | |
41 Neutral | AU$138.81M | -2.84 | 279.21% | ― | ― | 0.66% | |
40 Underperform | AU$70.74M | -3.40 | -35.86% | ― | ― | -19.21% |
Orthocell Ltd Corporate Events
Orthocell Ltd has notified the market that 16,567 retention rights, classified as OCCAAH securities, have lapsed after conditions attached to these rights were not met or became incapable of being satisfied. The cessation of these conditional securities, effective 31 December 2025, results in a small reduction of potential future equity issuance and slightly streamlines the company’s capital structure without impacting existing ordinary shareholders.
The announcement, lodged as a new Appendix 3H on 16 March 2026, reflects Orthocell’s ongoing obligations to keep investors informed of changes to its issued and potential capital. While the lapse of retention rights may signal that certain performance or service milestones were not achieved, it also limits dilution for current investors and underscores the contingent nature of incentive-based equity awards in ASX-listed companies.
The most recent analyst rating on (AU:OCC) stock is a Sell with a A$0.77 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has issued 654,963 retention rights and 240,065 performance rights as unquoted securities under its employee incentive scheme, effective 16 March 2026. The new rights, which are subject to transfer restrictions and will not be quoted on the ASX, underscore the company’s use of equity-based incentives to retain and motivate staff, aligning employee interests with long-term shareholder value.
The move signals Orthocell’s continued reliance on structured equity remuneration to support its growth and development efforts in regenerative medicine. While the issuance does not immediately affect the company’s quoted share capital, it may contribute to future dilution and reflects ongoing investment in human capital as a strategic asset in a competitive biotech sector.
The most recent analyst rating on (AU:OCC) stock is a Sell with a A$0.77 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell has appointed LEDA Orthopaedics as the exclusive distributor for its Remplir nerve repair device in the United Kingdom, a move that underpins its strategy to penetrate the UK and EU peripheral nerve repair market estimated at US$750 million annually. LEDA, a specialist orthopaedic distributor with more than 40 sales representatives and strong surgeon relationships, will begin pre-launch activities such as surgeon engagement, medical education and hospital procurement planning while Orthocell awaits anticipated UK/EU regulatory approval in Q3 FY26.
The UK rollout will be supported by Orthocell’s Australian-based commercial and medical education teams, leveraging programs and clinical evidence that have driven successful launches in Australia and the United States. With Remplir already approved and selling in multiple markets including Australia, New Zealand, Singapore, the US and Hong Kong, and first Canadian sales expected in the near term, Orthocell’s approximately $49 million in cash reserves provide a strong balance sheet to execute its global distribution strategy and accelerate commercial adoption in new territories.
The most recent analyst rating on (AU:OCC) stock is a Sell with a A$0.84 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has reported a change in the holdings of director Michael McNulty, who maintains both direct and indirect interests in the company’s securities through personal holdings, a family trust structure and his spouse. The disclosure forms part of the company’s ongoing compliance with ASX requirements to keep the market informed about changes in director interests.
McNulty acquired 26,041 ordinary shares on market on 25 February 2026 for a total consideration of $25,031.26, increasing his direct shareholding to 50,602 ordinary shares while retaining 2,000,000 unlisted options and his spouse’s 56,169 shares. The transaction, which did not occur during a closed period, may be interpreted by investors as a signal of confidence from the director and marginally increases insider ownership in Orthocell.
The most recent analyst rating on (AU:OCC) stock is a Sell with a A$0.86 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell has disclosed a change in director John Van Der Wielen’s interests following an on‑market purchase of 32,500 ordinary shares for $31,337. The transaction increases his direct equity exposure while leaving his 4,000,000 unlisted options, exercisable at $0.40 each by 29 May 2028, and his existing 541,666 ordinary shares unchanged, signalling continued alignment between board and shareholder interests.
The acquisition was executed outside a closed trading period and did not involve any related contracts or derivative arrangements. This incremental share purchase modestly strengthens insider ownership, which may be viewed positively by investors monitoring governance, director confidence and capital markets activity around Orthocell’s regenerative medicine portfolio.
The most recent analyst rating on (AU:OCC) stock is a Sell with a A$0.86 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell has reported record first-half FY26 revenue of $6.2 million, up 48% year-on-year, driven by rising adoption of its Striate+ and Remplir products and improved gross margins of 55%. The company remains loss-making, with a $5.2 million net loss after tax reflecting heavy investment in U.S. commercial infrastructure, automation and systems to support its global scale-up.
The U.S. launch of Remplir is advancing, with approvals secured in 45 states and growing hospital account penetration, while national distribution in Canada and new channels in Hong Kong bolster its international footprint. Orthocell is also targeting nerve-sparing prostate surgery and preparing EU and U.K. market entry, supported by a strong $49.4 million cash position and portfolio expansion via PearlBone, which together position the company for broader market access and long-term growth.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has issued a US market and operational update presentation, but the released text consists solely of standard legal and confidentiality disclaimers typically accompanying investor or corporate communications. The document outlines that the material is not an offer or solicitation for securities, must not be relied upon as comprehensive investment advice, is confidential and restricted in its use and distribution, and that any forward-looking statements are subject to significant risks and uncertainties, underscoring limited liability and no obligation to update such statements beyond legal requirements.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited will host an investor webinar on 2 February 2026 to provide an operational update, with a particular focus on the rollout of its Remplir nerve repair device in the United States. The briefing, led by the company’s chairman and chief executive, underscores the strategic importance of the US market to Orthocell’s growth, following recent regulatory clearances and the establishment of a specialist US distributor network that has already generated initial sales, and will give investors and stakeholders further insight into how its expanding product portfolio and regulatory progress are shaping its commercial trajectory in regenerative medicine.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell reported its seventh consecutive quarter of record revenue, posting $3.2 million for the December 2025 quarter, up 45% year on year, driven by accelerating adoption of its Remplir nerve repair device and initial US sales. Backed by $49.4 million in cash following a heavily supported $30 million capital raising, the company is ramping up global commercialisation of Remplir with a distributor network now covering more than 25 US states, early traction in Canada and Hong Kong, and a regulatory application lodged for entry into the sizeable EU and UK nerve repair markets; it also secured global distribution rights to PearlBone bone regeneration technology and is building a new commercial opportunity in nerve-sparing prostate cancer surgery that could expand its US addressable market to about US$2 billion.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell has executed a binding agreement with Marine Biomedical Pty Ltd, lifting its equity stake from 1.72% to 11.7% for AU$1.05 million and securing a first right of refusal over global distribution rights for PearlBone, a next-generation bone substitute made from sustainably sourced pearl shells, as well as future bone repair products. The deal converts a prior memorandum into a formal strategic partnership, broadening Orthocell’s offering into bone regeneration alongside its existing nerve and tendon repair technologies and positioning it as a multi-tissue regenerative medicine provider targeting complex trauma and reconstructive procedures. With Marine Biomedical progressing PearlBone toward a U.S. FDA 510(k) submission and potential entry into the US$1.6 billion global bone substitute market, Orthocell aims to capitalise on its U.S. distribution network, supported by robust cash reserves of $49.4 million to fund ongoing commercial expansion.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell reported record quarterly revenue of $3.2 million for the December 2025 quarter, its seventh consecutive quarter of record sales, driven by strong Remplir nerve repair product uptake in existing markets and initial U.S. sales. The company’s hybrid U.S. market entry strategy—combining specialist distributors with internal field leadership—is gaining traction, with distributor coverage now spanning more than 25 states, 23 hospital Value Analysis Committee approvals, and multiple medical education events completed, while Canadian market entry is underway. Supported by $49.4 million in cash reserves, no debt and an expected R&D tax refund, Orthocell is well positioned to accelerate Remplir adoption and pursue a step-change in revenue as it scales across North America.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.